Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × ProMune × Clear all
NCT00471159 2015-05-04

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Pfizer

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00043368 2009-03-12

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Pfizer

Phase 2 Completed
31 enrolled
BreastDermatologicGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Lymphoma, T-Cell

NCT00043394 2009-03-12

CPG 7909 Plus HerceptinĀ® In Patients With Metastatic Breast Cancer

Pfizer

Phase 2 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔